WO2008156655A3 - Vaccinia virus vectors encoding a sodium-dependent transporter protein for imaging and/or treatment of tumors - Google Patents

Vaccinia virus vectors encoding a sodium-dependent transporter protein for imaging and/or treatment of tumors Download PDF

Info

Publication number
WO2008156655A3
WO2008156655A3 PCT/US2008/007377 US2008007377W WO2008156655A3 WO 2008156655 A3 WO2008156655 A3 WO 2008156655A3 US 2008007377 W US2008007377 W US 2008007377W WO 2008156655 A3 WO2008156655 A3 WO 2008156655A3
Authority
WO
WIPO (PCT)
Prior art keywords
tumors
imaging
treatment
sodium
vaccinia virus
Prior art date
Application number
PCT/US2008/007377
Other languages
French (fr)
Other versions
WO2008156655A2 (en
WO2008156655A9 (en
Inventor
Yuman Fong
Nanhai Chen
Qian Zhang
Yong A Yu
Aladar A Szalay
Original Assignee
Genelux Corp
Sloan Kettering Inst Cancer
Yuman Fong
Nanhai Chen
Qian Zhang
Yong A Yu
Aladar A Szalay
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genelux Corp, Sloan Kettering Inst Cancer, Yuman Fong, Nanhai Chen, Qian Zhang, Yong A Yu, Aladar A Szalay filed Critical Genelux Corp
Priority to CA2690627A priority Critical patent/CA2690627C/en
Priority to EP08768418.9A priority patent/EP2171071B1/en
Priority to JP2010512192A priority patent/JP5213075B2/en
Publication of WO2008156655A2 publication Critical patent/WO2008156655A2/en
Publication of WO2008156655A9 publication Critical patent/WO2008156655A9/en
Publication of WO2008156655A3 publication Critical patent/WO2008156655A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Modified viruses encoding transporter proteins and methods for preparing the modified viruses are provided. Vaccines that contain the viruses are provided. The viruses also can be used in diagnostic methods, such detection and imaging of tumors. The viruses also can be used in methods of treatment of diseases, such as proliferative and inflammatory disorders, including as anti-tumor agents.
PCT/US2008/007377 2007-06-15 2008-06-13 Vaccinia virus vectors encoding a sodium-dependent transporter protein for imaging and/or treatment of tumors WO2008156655A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA2690627A CA2690627C (en) 2007-06-15 2008-06-13 Microorganisms for imaging and/or treatment of tumors
EP08768418.9A EP2171071B1 (en) 2007-06-15 2008-06-13 Vaccinia virus vectors encoding a sodium-dependent transporter protein for imaging and/or treatment of tumors
JP2010512192A JP5213075B2 (en) 2007-06-15 2008-06-13 Microorganisms for tumor imaging and / or treatment

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93476807P 2007-06-15 2007-06-15
US60/934,768 2007-06-15

Publications (3)

Publication Number Publication Date
WO2008156655A2 WO2008156655A2 (en) 2008-12-24
WO2008156655A9 WO2008156655A9 (en) 2009-03-19
WO2008156655A3 true WO2008156655A3 (en) 2009-06-18

Family

ID=40002958

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/007377 WO2008156655A2 (en) 2007-06-15 2008-06-13 Vaccinia virus vectors encoding a sodium-dependent transporter protein for imaging and/or treatment of tumors

Country Status (5)

Country Link
US (3) US20090117034A1 (en)
EP (1) EP2171071B1 (en)
JP (1) JP5213075B2 (en)
CA (1) CA2690627C (en)
WO (1) WO2008156655A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7754221B2 (en) 2003-06-18 2010-07-13 Genelux Corporation Microorganisms for therapy
US8859256B2 (en) 2011-10-05 2014-10-14 Genelux Corporation Method for detecting replication or colonization of a biological therapeutic

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1281767A3 (en) * 2001-07-31 2003-05-28 Aladar A. Szalay Light emitting microorganisms and cells for diagnosis and therapy of tumors
TW200819540A (en) 2006-07-11 2008-05-01 Genelux Corp Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders
EP2415783B1 (en) * 2006-10-16 2016-12-14 Genelux Corporation Modified vaccinia virus strains for use in a diagnostic and therapeutic method
WO2008150496A2 (en) * 2007-05-31 2008-12-11 Genelux Corporation Assay for sensitivity to chemotherapeutic agents
JP5213075B2 (en) * 2007-06-15 2013-06-19 ジェネラックス・コーポレイション Microorganisms for tumor imaging and / or treatment
EP2202297B1 (en) * 2007-07-18 2014-05-14 Genelux Corporation Use of a chemotherapeutic agent in the preparation of a medicament for treating or ameliorating an adverse side effect associated with oncolytic viral therapy
EP2212696B1 (en) * 2007-10-25 2013-12-04 Genelux Corporation Systems and methods for viral therapy
WO2009126189A1 (en) 2008-01-11 2009-10-15 Genelux Corporation Methods and compositions for detection of bacteria and treatment of diseases and disorders
WO2009139921A2 (en) * 2008-05-16 2009-11-19 Genelux Corporation Microorganisms for preventing and treating neoplasms accompanying cellular therapy
US20130263296A1 (en) * 2010-10-28 2013-10-03 The Johns Hopkins University Cancer imaging with therapy: theranostics
EP2670866A4 (en) * 2011-04-05 2015-09-02 Translational Genomics Res Inst Biomarkers and methods of use thereof
CN114262690A (en) 2011-04-15 2022-04-01 吉恩勒克斯公司 Clonal strains of attenuated vaccinia virus and methods of use thereof
WO2013138522A2 (en) 2012-03-16 2013-09-19 Genelux Corporation Methods for assessing effectiveness and monitoring oncolytic virus treatment
US20130280170A1 (en) 2012-04-20 2013-10-24 Aladar A. Szalay Imaging methods for oncolytic virus therapy
WO2014055960A1 (en) 2012-10-05 2014-04-10 Genelux Corporation Energy absorbing-based diagnostic and therapeutic methods employing nucleic acid molecules encoding chromophore-producing enzymes
US9925276B2 (en) * 2013-03-14 2018-03-27 Epeius Biotechnologies Corporation Thymidine kinase gene
WO2014183033A2 (en) * 2013-05-09 2014-11-13 Advanced Neuroregenerative Therapies, Llc Method of repairing age and disease immune dysfunction and cellular senescence with lymphoid stem cells and then re-applying those for therapeutic use
WO2015103438A2 (en) 2014-01-02 2015-07-09 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
US9549914B2 (en) 2014-04-03 2017-01-24 The Johns Hopkins University Treatment of human cytomegalovirus by modulating Wnt
SI3626731T1 (en) * 2014-12-23 2021-12-31 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers
US10639366B2 (en) 2015-02-25 2020-05-05 Memorial Sloan Kettering Cancer Center Use of inactivated nonreplicating modified vaccinia virus Ankara (MVA) as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
GB201504251D0 (en) * 2015-03-13 2015-04-29 Virttu Biolog Ltd And University Of Sheffield The Oncolytic herpes simplex virus infected cells
CN107847534B (en) 2015-04-17 2022-10-04 纪念斯隆凯特琳癌症中心 Use of MVA or MVA delta E3L as an immunotherapeutic agent against solid tumors
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
MX2018010204A (en) 2016-02-25 2019-05-06 Memorial Sloan Kettering Cancer Center Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human flt3l or gm-csf for cancer immunotherapy.
CN109152827B (en) 2016-02-25 2023-07-21 纪念斯隆凯特琳癌症中心 Recombinant MVA or MVA delta E3L expressing human FLT3L and use thereof as immunotherapeutic agent against solid tumors
JP2019521643A (en) 2016-04-15 2019-08-08 アルパイン イミューン サイエンシズ インコーポレイテッド CD80 variant immunoregulatory protein and uses thereof
BR112018070934A2 (en) 2016-04-15 2019-02-26 Alpine Immune Sciences, Inc. immunomodulatory proteins, single ligand variants and uses thereof
CN110088127A (en) 2016-07-28 2019-08-02 高山免疫科学股份有限公司 CD155 variant immune modulator and application thereof
US11834490B2 (en) 2016-07-28 2023-12-05 Alpine Immune Sciences, Inc. CD112 variant immunomodulatory proteins and uses thereof
US11471488B2 (en) 2016-07-28 2022-10-18 Alpine Immune Sciences, Inc. CD155 variant immunomodulatory proteins and uses thereof
SG11201903407XA (en) 2016-10-20 2019-05-30 Alpine Immune Sciences Inc Secretable variant immunomodulatory proteins and engineered cell therapy
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
CN110168092A (en) * 2016-12-28 2019-08-23 特朗斯吉有限公司 Oncolytic virus and treatment molecule
US11920156B2 (en) 2017-02-09 2024-03-05 Indapta Therapeutics, Inc. Engineered natural killer (NK) cells and compositions and methods thereof
CA3053804A1 (en) 2017-03-16 2018-09-20 Alpine Immune Sciences, Inc. Pd-l1 variant immunomodulatory proteins and uses thereof
BR112019018747A2 (en) 2017-03-16 2020-05-05 Alpine Immune Sciences Inc variant immunomodulatory proteins of cd80 and uses thereof
EP3596115A1 (en) 2017-03-16 2020-01-22 Alpine Immune Sciences, Inc. Pd-l2 variant immunomodulatory proteins and uses thereof
EP3621646A4 (en) 2017-05-12 2021-06-02 Memorial Sloan Kettering Cancer Center Vaccinia virus mutants useful for cancer immunotherapy
US11753458B2 (en) 2017-10-10 2023-09-12 Alpine Immune Sciences, Inc. CTLA-4 variant immunomodulatory proteins and uses thereof
CN111712515A (en) 2017-10-18 2020-09-25 高山免疫科学股份有限公司 Variant ICOS ligand immunomodulatory proteins and related compositions and methods
US20210363219A1 (en) 2018-06-15 2021-11-25 Alpine Immune Sciences, Inc. Pd-1 variant immunomodulatory proteins and uses thereof
US20220008466A1 (en) 2018-11-21 2022-01-13 Indapta Therapeutics, Inc Methods for expansion of natural killer (nk) cell subset and related compositions and methods
CN113727998A (en) 2018-11-30 2021-11-30 高山免疫科学股份有限公司 CD86 variant immunomodulatory proteins and uses thereof
CN111040953B (en) * 2019-12-12 2023-03-31 南昌大学 Method for rapidly screening variant microorganisms based on PET imaging system
CN116368221A (en) 2020-04-22 2023-06-30 因达普塔治疗公司 Natural Killer (NK) cell compositions and methods of producing the same
US20230279426A1 (en) * 2020-06-24 2023-09-07 Lycia Therapeutics, Inc. Modified viral compositions for viral transduction
CN114540228B (en) * 2022-02-21 2024-01-23 上海交通大学医学院附属仁济医院 Bacterium modified by photo-thermal agent, preparation method and application thereof
CN116803424B (en) * 2023-08-24 2023-11-28 上海懿贝瑞生物医药科技有限公司 SLC17A5 gene inhibitor and application thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001048246A1 (en) * 1999-12-29 2001-07-05 Vanderbilt University Genetic mutation underlying orthostatic intolerance and diagnostic and therapeutic methods relating thereto
WO2004000236A2 (en) * 2002-06-25 2003-12-31 The Ohio State University Research Foundation Modified sodium iodide symporter proteins and genes for imaging and cancer therapy
WO2005047458A2 (en) * 2003-06-18 2005-05-26 Genelux Corporation Modified recombinant vaccina viruses and other microorganisms, uses thereof
US20060193832A1 (en) * 2005-02-04 2006-08-31 University Of Iowa Research Foundation Use of the sodium iodine symporter to effect uptake of iodine

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS542336A (en) * 1977-06-06 1979-01-09 Meiji Seika Kaisha Ltd Preventive and remedy for viral diseases
EP0037441B1 (en) 1980-03-10 1984-05-09 Seiji Arakawa Pharmaceutical compositions useful as cellular immunopotentiator and anti-tumor agent, process for production thereof and microorganism used therein
US4315914A (en) * 1980-04-04 1982-02-16 Seiji Arakawa Pharmaceutical compositions useful as cellular immunopotentiator and antitumor agent and process for production thereof
US4722848A (en) * 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5364773A (en) * 1991-03-07 1994-11-15 Virogenetics Corporation Genetically engineered vaccine strain
US4769330A (en) * 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US5833975A (en) * 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US4603112A (en) * 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US5110587A (en) * 1981-12-24 1992-05-05 Health Research, Incorporated Immunogenic composition comprising synthetically modified vaccinia virus
US5174993A (en) * 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US7045313B1 (en) * 1982-11-30 2006-05-16 The United States Of America As Represented By The Department Of Health And Human Services Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA
JPH0746994B2 (en) * 1984-10-04 1995-05-24 味の素株式会社 Method for producing L-amino acid by fermentation method
US4767610A (en) 1984-10-19 1988-08-30 The Regents Of The University Of California Method for detecting abnormal cell masses in animals
US5221623A (en) * 1986-07-22 1993-06-22 Boyce Thompson Institute For Plant Research, Inc. Use of bacterial luciferase structural genes for cloning and monitoring gene expression in microorganisms and for tagging and identification of genetically engineered organisms
US5866136A (en) * 1986-08-01 1999-02-02 Commonwealth Scientific And Industrial Organisation Recombinant vaccine
CA1308516C (en) * 1987-07-06 1992-10-06 J. William Lown Oligopeptide anticancer and antiviral agents
CA1341251C (en) * 1988-02-12 2001-06-12 David Bernard Boyle Pox virus vectors
DK0486622T3 (en) * 1989-08-09 1999-07-19 Rhomed Inc Direct radiolabelling of antibodies and other proteins with technetium or rhenium
US5102651A (en) * 1989-12-29 1992-04-07 Neorx Corporation Process for isolation and radiolabeling of pharmaceuticals with isotopes of astatine
IE910820A1 (en) 1990-03-22 1991-09-25 Sloan Kettering Inst Cancer Gp75 as a tumor vaccine for melanoma
KR100242671B1 (en) 1991-03-07 2000-03-02 고돈 에릭 Genetically engineered vaccine strain
GB9105383D0 (en) * 1991-03-14 1991-05-01 Immunology Ltd An immunotherapeutic for cervical cancer
US5718902A (en) 1991-06-17 1998-02-17 The Regents Of The University Of California Double recombinant vaccinia virus vaccines
GB9114468D0 (en) 1991-07-04 1991-08-21 Wellcome Found Antibody production
JPH07501450A (en) * 1991-11-29 1995-02-16 モンサント　カンパニー Cyclic diguanylate metabolizing enzyme
EP0672161B1 (en) * 1992-11-05 1999-09-22 Xyrofin Oy Recombinant method and host for manufacture of xylitol
US5707928A (en) * 1993-09-28 1998-01-13 American Cyanamid Company Emulsifiable suspension concentrate compositions of imidazolinyl benzoic acids, esters and salts thereof, and dinitroaniline herbicides
WO1995027494A1 (en) 1994-04-11 1995-10-19 Sloan-Kettering Institute For Cancer Research DEFECTIVE HERPES AND DEFECTIVE ADENO-ASSOCIATED VIRUS VECTORS WITH p53 FOR THE TREATMENT OF CANCER
US6093700A (en) * 1995-05-11 2000-07-25 Thomas Jefferson University Method of inducing an immune response using vaccinia virus recombinants encoding GM-CSF
US6455673B1 (en) * 1994-06-08 2002-09-24 President And Fellows Of Harvard College Multi-mutant diphtheria toxin vaccines
US5650135A (en) 1994-07-01 1997-07-22 The Board Of Trustees Of The Leland Stanford Junior University Non-invasive localization of a light-emitting conjugate in a mammal
GB9415369D0 (en) * 1994-07-29 1994-09-21 Lynxvale Ltd Mutant virus
EP0872547B1 (en) * 1994-08-30 2007-12-26 Ajinomoto Co., Inc. Process for producing l-valine and l-leucine
ES2154738T3 (en) * 1994-10-03 2001-04-16 Us Gov Health & Human Serv COMPOSITION THAT INCLUDES A RECOMBINANT VIRUS EXPRESSING AN ANTIGEN AND A RECOMBINATING VIRUS EXPRESSING AN IMMUNO STIMULATORY MOLECULA.
US6503703B1 (en) * 1995-05-19 2003-01-07 Mount Sinai School Of Medicine Of New York University Identification and use of antiviral compounds that inhibit interaction of host cell proteins and viral proteins required for viral replication
US6190657B1 (en) * 1995-06-07 2001-02-20 Yale University Vectors for the diagnosis and treatment of solid tumors including melanoma
US6391579B1 (en) 1996-02-01 2002-05-21 Albert Einstein College Of Medicine Of Yeshiva University Thyroid sodium/iodide symporter and nucleic acid encoding same
WO1997032590A1 (en) 1996-03-04 1997-09-12 Sloan-Kettering Institute For Cancer Research Compositions and method for evaluating tissue for the presence of cancer cells
US6077697A (en) 1996-04-10 2000-06-20 Chromos Molecular Systems, Inc. Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
US5710137A (en) * 1996-08-16 1998-01-20 The Trustees Of Columbia University In The City Of New York Use of a melanoma differentiation associated gene (mda 7) for reversing a cancerous phenotype
US6051428A (en) 1997-03-21 2000-04-18 Sloan-Kettering Institute For Cancer Research Rapid production of autologous tumor vaccines
US6232523B1 (en) * 1997-04-28 2001-05-15 Anticancer, Inc. Metastasis models using green fluorescent protein (GFP) as a marker
US6251384B1 (en) * 1997-04-28 2001-06-26 Anticancer, Inc. Metastasis models using green fluorescent protein (GFP) as a marker
EP0979298B1 (en) * 1997-04-28 2008-06-11 Anticancer, Inc. Metastasis models using green fluorescent protein (gfp) as a marker
JP3966583B2 (en) * 1997-06-23 2007-08-29 協和醗酵工業株式会社 Method for producing L-amino acid by fermentation
US6713284B2 (en) * 1997-06-25 2004-03-30 The United States Of America As Represented By The Secretary Of The Army Bacterial superantigen vaccines
IL122818A0 (en) * 1997-07-10 1998-08-16 Yeda Res & Dev Chimeric interleukin-6 soluble receptor/ligand protein analogs thereof and uses thereof
US20030044384A1 (en) * 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
US7780962B2 (en) * 1997-10-09 2010-08-24 Wellstat Biologics Corporation Treatment of neoplasms with RNA viruses
US6726686B2 (en) * 1997-11-12 2004-04-27 Sherwood Services Ag Bipolar electrosurgical instrument for sealing vessels
US5922576A (en) * 1998-02-27 1999-07-13 The John Hopkins University Simplified system for generating recombinant adenoviruses
EP1153136A2 (en) * 1998-12-09 2001-11-14 The General Hospital Corporation Enhanced packaging of herpes virus amplicons and generation of recombinant virus vectors
US6428968B1 (en) * 1999-03-15 2002-08-06 The Trustees Of The University Of Pennsylvania Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
EP2325321A1 (en) * 1999-05-28 2011-05-25 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES A combined growth factor-deleted and thymidine kinase-deleted vaccinia virus vector
FR2794771B1 (en) * 1999-06-11 2001-08-10 Aventis Pharma Sa RECOMBINANT ADENOVIRUSES ENCODING THE IODINE SPECIFIC TRANSPORTER (NIS)
US6586411B1 (en) * 2000-08-16 2003-07-01 Mayo Foundation For Medical Education And Research System for monitoring the location of transgenes
JP2003522325A (en) 1999-08-23 2003-07-22 ポラリス ファーマシューティカルズ，インコーポレイテッド Inhibitor of binding between protein and macromolecular ligand
EP1955703A1 (en) 1999-11-12 2008-08-13 Oncolytics Biotech Inc. Viruses for the treatment of cellular proliferative disorders
AU3459701A (en) * 2000-01-26 2001-08-07 Chiron Corporation Recombinant aav packaging systems
RU2280690C2 (en) * 2000-03-02 2006-07-27 Полимун Сайнтифик Иммунбиологише Форшунг Гмбх Recombinant influenza virus a
JP2004515461A (en) 2000-06-01 2004-05-27 スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ Use of mutant herpesviruses and anticancer drugs in cancer treatment
EP1404375A1 (en) 2001-07-09 2004-04-07 Anticancer, Inc. Imaging infection using fluorescent protein as a marker
EP1281767A3 (en) * 2001-07-31 2003-05-28 Aladar A. Szalay Light emitting microorganisms and cells for diagnosis and therapy of tumors
US20030198627A1 (en) * 2001-09-01 2003-10-23 Gert-Jan Arts siRNA knockout assay method and constructs
US7015027B1 (en) * 2001-11-20 2006-03-21 Mds (Canada) Inc. Radiation therapy by accumulation of therapeutic radionuclides in tumor-targeting bacteria
AU2003217925A1 (en) 2002-03-01 2003-09-16 Sloan-Kettering Institute For Cancer Research Treatment of metastatic institute for cancer
ES2566487T3 (en) * 2002-04-12 2016-04-13 Omeros Corporation Method of identification of compounds that interact with transmembrane proteins
EP1369491A1 (en) * 2002-06-05 2003-12-10 Aladar A. Szalay Light emitting microorganisms and cells for diagnosis and therapy of diseases associated with wounded or inflamed tissue
US20030228261A1 (en) * 2002-06-05 2003-12-11 Aladar Szalay Light emitting microorganisms and cells for diagnosis and therapy of diseases associated with wounded or inflamed tissue
AU2003258168B2 (en) * 2002-08-12 2009-10-29 Sillajen Biotherapeutics, Inc. Methods and compositions concerning poxviruses and cancer
US7318917B2 (en) * 2002-09-06 2008-01-15 Vanderbilt University Rapid assays for neurotransmitter transporters
EP1526185B1 (en) 2003-10-22 2012-09-12 Genelux Corporation Use of a microorganism or cell to induce autoimmunization of an organism against a tumor
EP1694852B1 (en) 2003-11-17 2010-10-13 Crusade Laboratories Limited Mutant herpes simplex virus and use thereof in the treatment of squamous cell cancer
WO2005066100A1 (en) * 2003-12-24 2005-07-21 Ge Healthcare Limited Methods for carbon isotope labeling synthesis of ketones and amines by suzuki coupling reactions using carbon-isotope monoxide
WO2005086922A2 (en) * 2004-03-10 2005-09-22 Board Of Regents, University Of Texas System Oncolytic adenovirus armed with therapeutic genes
US20050281782A1 (en) * 2004-06-21 2005-12-22 Howard Kaufman Novel recombinant poxvirus composition and uses thereof
US9180149B2 (en) 2005-09-07 2015-11-10 Sillajen Biotherapeutics, Inc. Systemic treatment of metastatic and/or systemically-disseminated cancers using GM-CSF-expressing poxviruses
ATE516370T1 (en) 2005-12-22 2011-07-15 Sloan Kettering Inst Cancer METHOD FOR DETECTING CANCER CELLS USING A VIRUS
TW200819540A (en) 2006-07-11 2008-05-01 Genelux Corp Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders
WO2008011726A1 (en) 2006-07-27 2008-01-31 Ottawa Health Research Institute Staged immune-response modulation in oncolytic therapy
US7947255B2 (en) 2006-08-09 2011-05-24 Vanderbilt University Fluorescent substrates for neurotransmitter transporters
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
WO2008043851A1 (en) 2006-10-13 2008-04-17 N.V. Organon A non-homogeneous quencher free assay method for the noradrenaline transporter
EP2415783B1 (en) * 2006-10-16 2016-12-14 Genelux Corporation Modified vaccinia virus strains for use in a diagnostic and therapeutic method
WO2008150496A2 (en) * 2007-05-31 2008-12-11 Genelux Corporation Assay for sensitivity to chemotherapeutic agents
JP5213075B2 (en) 2007-06-15 2013-06-19 ジェネラックス・コーポレイション Microorganisms for tumor imaging and / or treatment
EP2202297B1 (en) * 2007-07-18 2014-05-14 Genelux Corporation Use of a chemotherapeutic agent in the preparation of a medicament for treating or ameliorating an adverse side effect associated with oncolytic viral therapy
EP2212696B1 (en) * 2007-10-25 2013-12-04 Genelux Corporation Systems and methods for viral therapy
WO2009126189A1 (en) 2008-01-11 2009-10-15 Genelux Corporation Methods and compositions for detection of bacteria and treatment of diseases and disorders
KR101031049B1 (en) 2008-04-17 2011-04-25 한국생명공학연구원 Labeling and Imaging of Cells using Multifunctional Perfluorocarbon nano Emulsions
WO2009139921A2 (en) * 2008-05-16 2009-11-19 Genelux Corporation Microorganisms for preventing and treating neoplasms accompanying cellular therapy
CN114262690A (en) 2011-04-15 2022-04-01 吉恩勒克斯公司 Clonal strains of attenuated vaccinia virus and methods of use thereof
US8859256B2 (en) 2011-10-05 2014-10-14 Genelux Corporation Method for detecting replication or colonization of a biological therapeutic
WO2013138522A2 (en) * 2012-03-16 2013-09-19 Genelux Corporation Methods for assessing effectiveness and monitoring oncolytic virus treatment
US20130280170A1 (en) 2012-04-20 2013-10-24 Aladar A. Szalay Imaging methods for oncolytic virus therapy
WO2014031693A1 (en) 2012-08-20 2014-02-27 Genelux Corporation Compositions containing protein polymers and vaccinia virus, and methods of use thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001048246A1 (en) * 1999-12-29 2001-07-05 Vanderbilt University Genetic mutation underlying orthostatic intolerance and diagnostic and therapeutic methods relating thereto
WO2004000236A2 (en) * 2002-06-25 2003-12-31 The Ohio State University Research Foundation Modified sodium iodide symporter proteins and genes for imaging and cancer therapy
WO2005047458A2 (en) * 2003-06-18 2005-05-26 Genelux Corporation Modified recombinant vaccina viruses and other microorganisms, uses thereof
US20060193832A1 (en) * 2005-02-04 2006-08-31 University Of Iowa Research Foundation Use of the sodium iodine symporter to effect uptake of iodine

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BLECHACZ B ET AL: "Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma", HEPATOLOGY, vol. 44, no. 6, December 2006 (2006-12-01), pages 1465 - 1477, XP002524754, ISSN: 0270-9139 *
MCCART J A ET AL: "Oncolytic Vaccinia Virus Expressing the Human Somatostatin Receptor SSTR2: Molecular Imaging after Systemic Delivery Using <111>In-Pentetreotide", MOLECULAR THERAPY, ACADEMIC PRESS, SAN DIEGO, CA, US, vol. 10, no. 3, 1 September 2004 (2004-09-01), pages 553 - 561, XP004660595, ISSN: 1525-0016 *
MOROZ M A ET AL: "Imaging hNET reporter gene expression with I-124-MIBG", JOURNAL OF NUCLEAR MEDICINE, vol. 48, no. 5, May 2007 (2007-05-01), pages 827 - 836, XP002505302, ISSN: 0161-5505 *
SERGANOVA I ET AL: "Non-invasive molecular imaging and reporter genes", CENTRAL EUROPEAN JOURNAL OF BIOLOGY, CENTRAL EUROPEAN SCIENCE JOURNALS, WA, vol. 1, no. 1, 1 March 2006 (2006-03-01), pages 88 - 123, XP019415691, ISSN: 1644-3632 *
ZHANG Q ET AL: "Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus", CANCER RESEARCH, vol. 67, no. 20, October 2007 (2007-10-01), pages 10038 - 10046, XP002505303, ISSN: 0008-5472 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7754221B2 (en) 2003-06-18 2010-07-13 Genelux Corporation Microorganisms for therapy
US8323959B2 (en) 2003-06-18 2012-12-04 Genelux Corporation Microorganisms for therapy
US8859256B2 (en) 2011-10-05 2014-10-14 Genelux Corporation Method for detecting replication or colonization of a biological therapeutic

Also Published As

Publication number Publication date
WO2008156655A2 (en) 2008-12-24
CA2690627A1 (en) 2008-12-24
CA2690627C (en) 2014-12-02
US20100233078A1 (en) 2010-09-16
EP2171071A2 (en) 2010-04-07
US20120244068A1 (en) 2012-09-27
EP2171071B1 (en) 2015-08-05
US20130129614A9 (en) 2013-05-23
JP5213075B2 (en) 2013-06-19
US8852927B2 (en) 2014-10-07
JP2010530745A (en) 2010-09-16
US8865153B2 (en) 2014-10-21
WO2008156655A9 (en) 2009-03-19
US20090117034A1 (en) 2009-05-07

Similar Documents

Publication Publication Date Title
WO2008156655A3 (en) Vaccinia virus vectors encoding a sodium-dependent transporter protein for imaging and/or treatment of tumors
WO2012142529A3 (en) Clonal strains of attenuated vaccinia viruses and methods of use thereof
WO2008100292A3 (en) Modified vaccinia virus strains for use in diagnostic and therapeutic methods
MX2023000781A (en) Humanized, mouse or chimeric anti-cd47 monoclonal antibodies.
WO2012027379A3 (en) Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines
IL201778A0 (en) Peptide imaging agents
WO2016061286A3 (en) Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
MY156286A (en) Human il-23 antigen binding proteins
WO2016107818A8 (en) Compositions and methods for protein glycosylation
IL189313A (en) Virus-like particles as vaccines for paramyxovirus, method for their preparation and use thereof
WO2009016180A3 (en) Peptide imaging agents
WO2009105152A3 (en) Virus-like particles as vaccines for paramyxovirus
WO2016130539A3 (en) Multi-specific antibodies with affinity for human a33 antigen and dota metal complex and uses thereof
WO2010039224A3 (en) Respiratory syncytial virus (rsv) sequences for protein expression and vaccines
WO2012083302A3 (en) Compositions and methods for the treatment or prevention of human adenovirus-36 infection
WO2012058627A3 (en) Pre-targeted nanoparticle system and method for labeling biological particles
WO2006058231A3 (en) Viral vectors
HK1145316A1 (en) Compounds for use in imaging, diagnosing, and or treatment of diseases of the central nervous system or of tumors
WO2016116905A9 (en) Cmv antigens and uses thereof
UA114286C2 (en) Methods and compositions for vaccinating against staphylococcus aureus
WO2011091389A3 (en) Cyclovirus and method of use
WO2010005704A3 (en) Novel helper plasmid, defective sindbis viral vectors and methods of use thereof
WO2013040478A3 (en) Hyr1-derived compositions and methods of treatment using same
EP2528939A4 (en) Recombinant proteins for use in vaccine, antibodies against said proteins, and diagnostic and therapeutic methods including the same
WO2016149643A3 (en) Fusion proteins comprising modified alpha virus surface glycoproteins and tumor associated antigen and methods thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08768418

Country of ref document: EP

Kind code of ref document: A2

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2690627

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2010512192

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008768418

Country of ref document: EP